Please login to the form below

trastuzumab emtansine

This page shows the latest trastuzumab emtansine news and features for those working in and with pharma, biotech and healthcare.

trastuzumab emtansine). ... Trastuzumab deruxtecan is central to Daiichi’s growth efforts, and is also a key drug for AZ’s cancer franchise.

Seattle Genetics wins FDA priority review for oral HER2 drug

Seattle is seeking approval for tucatinib in combination with Roche’s anti-HER2 antibody (trastuzumab) plus Xeloda (capecitabine). ... ado-trastuzumab emtansine).
Roche posts minor sales miss in Q4 as biosimilar pressure grows

Looking forward to this year and beyond, additional indications for Tecentriq and HER2-positive breast cancer antibody-drug conjugate Kadcyla (trastuzumab emtansine) will also help drive future growth, said Roche, although ... the latter is facing new
AZ, Daiichi Sankyo get early okay for DS-8201, now named Enhertu

The US regulator has cleared the HER2 inhibitor drug – now known as Enhertu (trastuzumab deruxtecan) – for metastatic HER2-positive disease in patients who have previously been treated with two or more ... Perjeta (pertuzumab) and Kadcyla
EMA backs adjuvant use of Roche’s breast cancer ADC Kadcyla

The EMA has cleared Kadcyla (ado-trastuzumab emtansine) for the adjuvant or post-surgery treatment of adults with HER2-positive early breast cancer, who still have some residual signs of invasive ... cancer cells despite treatment before surgery with
AZ, Daiichi Sankyo strengthen case for HER2 candidate

Its nearest rival in the area is Roche’s anti-HER2 ADC Kadcyla (trastuzumab emtansine). Both drugs work by combining the HER2-targeting of trastuzumab with a cell-killing chemotherapy component ... Kadcyla is the smallest in terms of sales in

More from news
Approximately 5 fully matching, plus 53 partially matching documents found.

20 for 2020 – Five pharma companies to watch

The company’s biggest play last year was licensing Daiichi Sankyo’s cancer candidate trastuzumab deruxtecan for an eyewatering. ... Roche already has a somewhat underperforming trastuzumab-based ADC in the form of Kadcyla (trastuzumab emtansine)
An eye towards the biobetter in South Korea

It was noteworthy that the Celltrion's announcement happened to coincide with Roche's clinical data presentation of its Herceptin biobetter, Trastuzumab-emtansine (T-DM1). . ... CT-P26. Celltrion. Trastuzumab-dolastatin 10 antibody drug conjugate. S

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Are biobetters a market access opportunity?

trastuzumab emtansine), received its first EU approval. for HER2+ metastatic breast cancer patients who did not respond to Herceptin and/or taxane.
The 2019 WHO essential medicine list: Narrowing the access gap to innovative cancer treatments

Roche’s Kadcyla (trastuzumab emtansine). the Committee stated that while it demonstrates relevant survival benefit, its use as second-line treatment of metastatic disease was considered not to be a priority

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Add my company

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping: Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much: Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website: You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...